1270019-95-8

Basic information

• Product Name: TERT-BUTYL (5-METHYLPIPERIDIN-3-YL)CARBAMATE
• Synonyms: TERT-BUTYL (5-METHYLPIPERIDIN-3-YL)CARBAMATE
• CAS NO: 1270019-95-8
• Molecular Formula: C11H22N2O2
• Molecular Weight: 214.30458
• EINECS: -0
• Mol File: 1270019-95-8.mol
• Article Data: 32

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL (5-METHYLPIPERIDIN-3-YL)CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL (5-METHYLPIPERIDIN-3-YL)CARBAMATE(1270019-95-8)
• EPA Substance Registry System: TERT-BUTYL (5-METHYLPIPERIDIN-3-YL)CARBAMATE(1270019-95-8)

Safety Data

• Hazardous Substances Data: 1270019-95-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl (5-methylpiperidin-3-yl)carbamate is a chemical compound used in the pharmaceutical industry as a potential drug candidate due to its promising pharmacological properties. TERT-BUTYL (5-METHYLPIPERIDIN-3-YL)CARBAMATE is a carbamate derivative with a tert-butyl group attached to a piperidine ring, and it is known for its potential as a central nervous system depressant. Research has shown that tert-butyl (5-methylpiperidin-3-yl)carbamate exhibits significant sedative and anxiolytic properties, making it a potential candidate for the development of new therapeutics for conditions such as anxiety disorders or insomnia. Further studies are needed to fully understand the mechanisms of action and potential therapeutic applications of this chemical compound.

Upstream product

• 951163-63-6 (3S,5S)-(1-benzyl-5-methyl-piperidin-3-yl)-carbamic acid tert-butyl ester 
• 59279-60-6 dimethyl (2S)-2-[(tert-butoxycarbonyl)amino]pentanedioate 
• 74-88-4 methyl iodide 
• 1229616-47-0 (2S,4S)-2-tert-butoxycarbonylamino-4-methyl-pentanedinitrile 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1270019-95-8 (3S,5S)-(5-Methyl-piperidin-3-yl)-carbamic acid tert-butyl ester 
• 631910-23-1 tert-butyl N-(5-methylpyridin-3-yl)carbamate 
• 3430-19-1 5-methylpyridin-3-amine 
• 1203651-06-2 tert-butyl [(3S,5R)-1-benzyl-5-methylpiperidin-3-yl]carbamate 
• 98-79-3 L-Pyroglutamic acid 
• 196394-49-7 (2S,4R)-1-(tert-butyl) 2-methyl 4-methyl-5-oxopyrrolidine-1,2-dicarboxylate 
• 951163-64-7 tert-butyl [(1S,3R)-4-hydroxy-1-(hydroxymethyl)-3-methylbutyl]carbamate 
• 4931-66-2 methyl (S)-pyroglutamate 

Downstream Products

• 1228449-97-5 (3R,5R)-3-amino-5-methyl-piperidine-1-carboxylic acid benzyl ester hydrochloride 
• 1620240-26-7 benzyl [2-{[(4-{(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-methylpiperidin-1-yl}pyridin-3-yl)amino]carbonyl}-7-(4-methylpiperazin-1-yl)quinolin-3-yl]carbamate 
• 1620240-40-5 benzyl (7-bromo-2-{[(4-{(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-methylpiperidin-1-yl}pyridin-3-yl)amino]carbonyl}quinolin-3-yl)carbamate 
• 1620240-52-9 benzyl [2-{[(4-{(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-methylpiperidin-1-yl}pyridin-3-yl)amino]carbonyl}-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)quinolin-3-yl]carbamate 
• 1620240-60-9 benzyl [2-{[(4-{(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-methylpiperidin-1-yl}pyridin-3-yl)amino]carbonyl}-7-(2-oxopiperidin-1-yl)quinolin-3-yl]carbamate 
• 1620240-63-2 benzyl [2-{[(4-{(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-methylpiperidin-1-yl}pyridin-3-yl)amino]carbonyl}-7-(4-methyl-3-oxopiperazin-1-yl)quinolin-3-yl]carbamate 
• 1620240-67-6 benzyl [2-[({4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]pyridin-3-yl}amino)carbonyl]-7-(3-oxopiperazin-1-yl)quinolin-3-yl]carbamate 
• 1620240-74-5 benzyl [2-[({4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]pyridin-3-yl}amino)carbonyl]-7-(3-oxomorpholin-4-yl)quinolin-3-yl]carbamate 
• 1620240-14-3 benzyl (2-{[(4-{(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-methylpiperidin-1-yl}pyridin-3-yl)amino]carbonyl}-7-morpholin-4-ylquinolin-3-yl)carbamate 
• 1620013-88-8 4-{(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-methylpiperidin-1-yl}-3-[({6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridin-2-yl}carbonyl)amino]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate 
• 1620013-89-9 tert-butyl ((3S,5R)-1-{3-[({6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridin-2-yl}carbonyl)amino]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl}-5-methylpiperidin-3-yl)carbamate 
• 1620012-62-5 N-{4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide 
• 1620012-71-6 3-amino-N-{4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide 
• 1620013-04-8 5-amino-N-{4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-2-(2,6-difluoro-3-methoxyphenyl)-1,3-thiazole-4-carboxamide 

Relevant articles and documents

SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS

The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as toll-like receptor 7/8 (TLR7/8) antagonists. In Formula (I), Ring A is aryl or heteroaryl; Ring B is aryl or heteroary; and X is C(R4)2, O, NR4, S, S(R4), or S(R4)2.

Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors

High levels of Pim expression have been implicated in several hematopoietic and solid tumor cancers, suggesting that inhibition of Pim signaling could provide patients with therapeutic benefit. Herein, we describe our progress towards this goal using a screening hit (rac-1) as a starting point. Modification of the indazole ring resulted in the discovery of a series of imidazopyridazine-based Pim inhibitors exemplified by compound 22m, which was found to be a subnanomolar inhibitor of the Pim-1 and Pim-2 isoforms (IC50values of 0.024?nM and 0.095?nM, respectively) and to potently inhibit the phosphorylation of BAD in a cell line that expresses high levels of all Pim isoforms, KMS-12-BM (IC50?=?28?nM). Profiling of Pim-1 and Pim-2 expression levels in a panel of multiple myeloma cell lines and correlation of these data with the potency of compound 22m in a proliferation assay suggests that Pim-2 inhibition would be advantageous for this indication.